Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Other Non-Current Liabilities data on record, last reported at $2.5 million in Q4 2024.

  • For Q4 2024, Other Non-Current Liabilities fell 34.81% year-over-year to $2.5 million; the TTM value through Dec 2024 reached $2.5 million, down 34.81%, while the annual FY2024 figure was $2.5 million, 34.81% down from the prior year.
  • Other Non-Current Liabilities reached $2.5 million in Q4 2024 per MIRM's latest filing, down from $4.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $140.4 million in Q4 2022 and bottomed at $22000.0 in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $26.5 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: soared 553816.67% in 2022, then crashed 99.18% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $47.7 million in 2020, then plummeted by 95.81% to $2.0 million in 2021, then surged by 6931.61% to $140.4 million in 2022, then plummeted by 97.26% to $3.8 million in 2023, then plummeted by 34.81% to $2.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $2.5 million in Q4 2024, $4.0 million in Q3 2024, and $4.0 million in Q2 2024.